Related Experiment Videos
Experience with fibrinolytic therapy of vascular occlusive disease
Insights
Streptokinase therapy shows potential for chronic arterial occlusion, but selection criteria need development. Its use in AV cannulae is established but historical, while lytic therapy shows promise for retinal vascular and hemolytic uremic syndromes.
Area of Science:
- Vascular Medicine
- Thrombolytic Therapy
Background:
- Streptokinase is a thrombolytic agent with established uses.
- Its application in chronic arterial occlusion, AV cannulae, and specific syndromes requires further definition.
Purpose of the Study:
- To review the current and potential applications of streptokinase therapy.
- To highlight areas needing further research and development of selection criteria.
Main Methods:
- Literature review and analysis of existing data on streptokinase efficacy and safety.
- Evaluation of preliminary results for emerging applications.
Main Results:
- Streptokinase efficacy is established for occluded AV cannulae, though this is of historical significance.
- Preliminary data suggest potential benefits in retinal vascular occlusion and hemolytic uremic syndrome, warranting further investigation.
- Further research is needed to establish clear selection criteria for streptokinase in chronic arterial occlusion.
Conclusions:
- Streptokinase therapy may benefit selected patients with chronic arterial occlusion, pending development of selection criteria.
- While established for AV cannulae, its contemporary relevance is limited.
- Lytic therapy, including streptokinase, shows encouraging preliminary results for retinal vascular occlusion and hemolytic uremic syndrome.
Abstract:
1. There may well be a place for streptokinase therapy in selected patients with chronic arterial occlusion, but the emphasis should be on developing information on selection criteria. 2. Efficacy and safety have been established for the use of streptokinase in occluded AV cannulae, but this may be more of historical than contemporary importance. 3. Although more investigation is required to define the role of lytic therapy in retinal vascular occlusion and in the hemolytic uremic syndrome, the preliminary results are encouraging and merit further attention.